On August 3 2023, ASSERTIO HOLDINGS ($NASDAQ:ASRT) reported their Q2 FY2023 earnings results, demonstrating a 16.7% year-on-year increase in total revenue to USD 41.0 million and a 8.2% increase in net income from the same period in the previous year, amounting to USD 8.5 million.
Analysis – Assertio Holdings Stock Fair Value Calculation
Analyzing ASSERTIO HOLDINGS‘s fundamentals with GoodWhale can help investors make more informed decisions. Based on our proprietary Valuation Line, we calculate the intrinsic value of ASSERTIO HOLDINGS share to be around $1.8. This indicates that ASSERTIO HOLDINGS stock is currently trading significantly higher than its true value at $5.4, an overvaluation of 198.4%. This discrepancy suggests a potential opportunity for investors to capitalize on the mispricing of the stock. With GoodWhale, investors can easily compare ASSERTIO HOLDINGS’s fundamentals with other stocks and make informed decisions. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Assertio Holdings. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Assertio Holdings. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Assertio Holdings. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Assertio Holdings are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The company’s products are distributed through its network of wholesalers, retailers, and distributors in the United States and internationally. Assertio Holdings Inc. is a publicly traded company on the NASDAQ Global Market under the ticker symbol ASRT. The company’s competitors include Chandra Bhagat Pharma Ltd, DHG Pharmaceutical JSC, and Yuhan Corp.
– Chandra Bhagat Pharma Ltd ($BSE:542934)
Chandra Bhagat Pharma Ltd is a pharmaceutical company with a market cap of 754.51M as of 2022. The company has a Return on Equity of 9.62%. The company manufactures and markets a range of pharmaceutical products, including antibiotics, anti-infectives, cardiovascular drugs, and more.
– DHG Pharmaceutical JSC ($HOSE:DHG)
DGH Pharmaceutical JSC is a pharmaceutical company that manufactures and sells drugs and other medical products. The company has a market cap of 10.94T as of 2022 and a return on equity of 16.55%. The company’s products include prescription and over-the-counter drugs, vitamins, and other nutritional supplements.
As of 2022, Yuhan Corp has a market capitalization of 3.85 trillion and a return on equity of 4.29%. The company is engaged in the development, manufacture, and sale of pharmaceutical and other health-related products.
Assertio Holdings‘ recent financial performance for the second quarter of fiscal year 2023 has been positive. Revenue grew by 16.7%, totaling 41 million USD, and net income increased 8.2%, amounting to 8.5 million USD. This strong performance is encouraging for investors, indicating that Assertio Holdings is generating healthy returns. It appears that their current strategy is well-suited for long-term success, and investors should remain confident in their investments.